Back to Search
Start Over
Bayer initiates OASIS 4 phase III study of elinzanetant in breast cancer patients with vasomotor symptoms caused by endocrine therapy
- Source :
- PharmaBiz. October 18, 2022
- Publication Year :
- 2022
-
Abstract
- Bayer, a global leader in women's healthcare, announced that it expands the phase III clinical development programme OASIS by initiating OASIS 4 -- a phase III study in breast cancer [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.723049032